Mesoblast (ASX:MSB) has announced that its FDA-approved Ryoncil (remestemcel-L) mesenchymal stromal cell therapy is now available for purchase in the US. …
Mesoblast says its FDA-approved mesenchymal stromal cell therapy available for sale in the US
March 27, 2025 Australian Biotech
Latest Video
New Stories
-
BioNSW launches BioInvest Catalyst events to support life sciences investment in NSW
March 31, 2025 - - Australian Biotech -
Election writs trigger timeline for the release of remaining budgeted decisions
March 31, 2025 - - Latest News -
New government report reveals the emerging impact of generational reform
March 31, 2025 - - Latest News -
Broader PBS listing recognises cardioprotective benefits of SGLT-2 inhibitor therapy
March 31, 2025 - - Latest News -
The Dispatched 'Week in Review' Podcast - 28 March
March 28, 2025 - - Podcast -
Work of the HTA Review implementation group will continue during caretaker
March 28, 2025 - - Latest News -
Health department quietly launches major review of blood products supply
March 27, 2025 - - Latest News